Diligence memo · auto-generated · as of July 2, 2026
Asklepios BioPharmaceutical, Inc.
Asklepios BioPharmaceutical, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Asklepios BioPharmaceutical, Inc. operates in Biotechnology, based in DURHAM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Asklepios BioPharmaceutical, Inc. has raised $200M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $200M on 2019-04-10.
Most recent recorded round closed around 2019-04-10.
Valuation (modeled)modeled
Provath models Asklepios BioPharmaceutical, Inc. at approximately $8.2B (range $905M–$18.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.96× the median modeled value of Series D+ Biotechnology companies in 2019–2021 (58 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 7.2 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 97% of Biotechnology peers (4293 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Sarepta Therapeutics, Inc., Affinivax, Inc., Sonoma Biotherapeutics, Inc., Instil Bio, Inc., Umoja Biopharma, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.